07:00 , Oct 14, 2013 |  BC Week In Review  |  Company News

Competitive Technologies management update

Competitive Technologies Inc. (OTCQX:CTTC), Fairfield, Conn.   Business: Neurology, Supply/Service   Hired: Conrad Mir as president, CEO, interim CFO and a director, formerly CFO of Pressure BioSciences Inc. ; he succeeds Carl O'Connell, who remains...
08:00 , Jan 28, 2008 |  BC Week In Review  |  Company News

Competitive Technologies Inc., Palatin deal

The companies ended a 1997 deal that gave Palatin rights to MT-II (PT-14) and settled all related litigation (see BioCentury, Nov. 17, 1997). Palatin paid $800,000 and returned rights to MT-II to Competitive Technologies. Palatin...
08:00 , Jan 2, 2006 |  BC Week In Review  |  Company News

Competitive Technologies Inc., Genzyme deal

CTT granted GENZ a license to U.S. Patent No. 4,940,658 covering homocysteine tests. CTT will receive an upfront payment and is eligible for royalties. Homocysteine is a marker for cardiovascular and neurodegenerative diseases. Competitive Technologies...
07:00 , Sep 5, 2005 |  BC Week In Review  |  Company News

Competitive Technologies Inc., Dade Behring deal

CTT granted DADE a license to its U.S. Patent No. 4,940,658 and ex-U.S. counterparts covering homocysteine tests for cardiovascular diseases. CTT will receive a license fee and is eligible for royalties. Competitive Technologies Inc. (CTT),...
07:00 , Aug 8, 2005 |  BC Week In Review  |  Company News

Competitive Technologies Inc., EpiTan, Melanotan Corp. deal

CTT licensed an additional patent covering melanogenesis-inducing technologies to Melanotan, which is the exclusive licensee of CTT's melanogenesis patent portfolio. The patent covers a series of cyclic bridged analogs to compounds covered in the original...
07:00 , Aug 8, 2005 |  BC Week In Review  |  Company News

Competitive Technologies Inc., J&J deal

CTT granted JNJ company Ortho-Clinical Diagnostics Inc. a license under U.S. Patent No. 4,940,658 and its ex-U.S. counterparts covering homocysteine tests. CTT will receive a license fee and is eligible for royalties. Competitive Technologies Inc....
07:00 , Aug 1, 2005 |  BC Week In Review  |  Company News

Competitive Technologies, Beckman Coulter deal

CTT granted BEC a license to U.S. Patent No. 4,940,658 and its ex-U.S. counterparts covering homocysteine tests. CTT will receive a license fee and is eligible for royalties. Competitive Technologies Inc. (CTT), Fairfield, Conn.  ...
07:00 , Jun 27, 2005 |  BC Week In Review  |  Company News

Palatin, Competitive Technologies Inc. genitourinary news

The companies settled their previously announced arbitration related to a 1997 license agreement for PTN to exclusively use CTT's Erectide peptide hormone analog in PTN's PT-141 erectile dysfunction compound (see BioCentury, Nov. 17, 1997). PTN...
07:00 , May 2, 2005 |  BC Week In Review  |  Company News

Axis-Shield, Competitive Technologies Inc. diagnostic news

The companies dropped their patent infringement suits. ASD received a license to CTT's U.S. Patent No. 4,940,658 covering assays for homocysteine, a marker for cardiovascular and neurodegenerative diseases. CTT will receive a license fee and...
08:00 , Dec 20, 2004 |  BC Week In Review  |  Company News

Competitive Technologies Inc., Abbott deal

ABT received a license to CTT's U.S. Patent No. 4,940,658 covering assays for homocysteine, a marker for cardiovascular and neurodegenerative diseases. ABT already markets homocysteine tests and said the deal will allow its customers to...